Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
about
CSPG4: a prototype oncoantigen for translational immunotherapy studies.The regulatory mechanisms of NG2/CSPG4 expression.Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
P2860
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Anti-chondroitin sulfate prote ...... ially in normoxia and hypoxia.
@en
type
label
Anti-chondroitin sulfate prote ...... ially in normoxia and hypoxia.
@en
prefLabel
Anti-chondroitin sulfate prote ...... ially in normoxia and hypoxia.
@en
P2093
P2860
P356
P1476
Anti-chondroitin sulfate prote ...... ially in normoxia and hypoxia.
@en
P2093
Christine Hafner
Daniela Pucciarelli
Lucia Csaderova
Maria Bartosova
Martina Takacova
Nina Lengger
Silvia Pastorekova
P2860
P356
10.3892/IJO.2015.3010
P577
2015-05-18T00:00:00Z